The American Gastroenterological Association has released updated guidelines for treating moderate-to-severe Crohn’s disease, outlining 16 evidence-based recommendations that prioritize advanced ...

In its new guideline, the AGA recommends infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or ...

The (AGA) has released a comprehensively updated clinical guideline on the pharmacological management of moderate-to-severe Crohn's disease.

The American Gastroenterological Association's new guideline uses cutting-edge network meta-analyses to recommend prescribing ...

Crohn’s Disease can affect any part of the gastrointestinal tract, but most commonly targets the terminal ileum and proximal colon. A key characteristic of Crohn’s is transmural involvement, meaning ...

How Does Tremfya Work for Crohn's Disease? Tremfya is a type of medicine called a monoclonal antibody. It works by targeting a protein in your body called interleukin-23 (IL-23). IL-23 is a cytokine ...

Several major advances in Crohn's disease have marked 2025, including two new FDA-approved therapies, emerging biologics that target novel pathways, and the first global standards for managing ...

“Short courses of steroids are typically given to patients with Crohn's disease who have symptoms from active intestinal inflammation,” says Jill Gaidos, MD, a gastroenterologist at Yale Medicine in ...

Fat is more complicated than we thought. Once considered just a bag of calories, scientists now know that our fat—aka adipose tissue—doesn't just squirrel away energy; it also sends and receives ...